Paragon Genomics CleanPlex SARS-CoV-2 NGS Panel
Paragon Genomics has launched its CleanPlex SARS-CoV-2 Panel for COVID-19 coronavirus detection, tracking, and research through amplicon-based target enrichment for next-generation sequencing applications. According to the firm, the panel covers the entire genome of the SARS-CoV-2 virus responsible for the global COVID-19 pandemic. The panel's four-step workflow converts viral RNA into sequencing-ready libraries within five hours, Paragon said. Powered by Paragon's CleanPlex's technology, versions of the panel are available for both the Illumina and MGI sequencing platforms.
Paragon is also offering free consultation for researchers interested in designing custom NGS panels for coronavirus research.
DNAstack COVID-19 Beacon
DNAstack has released Beacon for SARS-CoV-2, the virus that causes COVID-19, to enable the scientific and medical communities to share and discover knowledge about the genetics of the virus in real time. Beacon, which is available here, will allow information about genetic variants to be shared instantly using software that follows an open international standard, the company said.
Researchers can use the new Beacon to discover sequences with specific genetic mutations and map their geographic and evolutionary origins. The platform integrates derivative data from genetic sequencing libraries such as GISAID and links to Nextstrain pathogen evolution visualizations.
The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH). The system is deployed on Microsoft Azure, a cloud computing platform with global reach and scalability.
Oncocyte said it has completed CLIA Validation for and launched DetermaIO, previously the Insight Genetics IM Score Test. The test is now available for research use within the biopharmaceutical and academic communities. DetermaIO is a gene expression profile test that evaluates the immune microenvironment in biopsies from cancer patients to identify individuals more or less likely to respond to anti-PD-1/PD-L1 immunotherapy. The test differentiates itself from other immunotherapy diagnostic tests by having the capability to determine if the immune microenvironment is active or quiescent. DetermaIO has the potential to be used to stratify patients in the more than 3,000 PD-1/PD-L1 ongoing clinical trials that are collectively expected to recruit over 500,000 patients, the company said.
For more new products and services, please visit the New Products page on our website.